Posted on

Better Plant Congratulates Affiliate Neonmind On Recent Achievements

Better Plant Congratulates Affiliate Neonmind On Recent Achievements

Vancouver, B.C. – November 10, 2021: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FRA: YG3) (“Better Plant” or the “Company”), a wellness company, congratulated its affiliate NeonMind Biosciences Inc. (“NeonMind”) on its recent achievements and advancements toward its drug development program and planned specialty clinics launch.

On November 8, 2021, NeonMind formed an alliance with SRx Health Solutions (“SRx”). SRx is a leading Canadian specialty healthcare services and medical treatment provider, to establish and operate a network of NeonMind-branded specialty clinics to deliver evidence-backed innovative treatments for a variety of mental health needs. NeonMind will leverage SRx’s nationwide network of over 70 clinics, as well as its operational capabilities, to bring NeonMind’s unique treatment protocols to underserved populations in Canada.

Prior to its alliance with SRx, NeonMind was ranked third in Psychedelia Magazine’s “8 Industry Innovators” segment within the magazine’s inaugural Winter 2022 issue. NeonMind was recognized for its dual approach in bringing psychedelic treatments to patients in need through its anticipated specialty mental health clinic launch and its drug development program for novel obesity treatments.

Better Plant congratulates NeonMind for these advancements toward providing integrated mental health services and delivering evidence-backed, innovative treatments tailored to local market needs. NeonMind is a Better Plant portfolio company with an ownership of 26 percent. NeonMind is listed on the CSE under the ticker symbol “NEON”, and on the OTCQB under the ticker symbol “NMDBF”.

 

About NeonMind Biosciences Inc.

NeonMind operates two divisions: (i) a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; and (ii) a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings.

In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind’s lead candidate, NEO-001, employs psilocybin as an agonist at the serotonin 5- HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The Company’s second drug candidate, NEO-002, employs low-dose psilocybin as an agonist at the 5-HT2C receptor, which controls appetite.

NeonMind established a medical services division with the goal of launching NeonMind-branded specialty mental health clinics in Canada that incorporate evidence-backed innovative treatments to address a variety of mental health needs.

For more information on NeonMind, go to  www.NeonMindBiosciences.com.

 

About Better Plant Sciences Inc.

Better Plant harnesses plant intelligence and leverages modern science to offer sustainable, plant-based products that are better for health and better for the earth. It makes and sells over 75 proprietary products, all made with 100% natural ingredients, under the brands Jusu, Urban Juve and Wright & Well.  Better Plant operates Jusu Bar, a quick serve restaurant alternative in Victoria, BC, which serves up fresh, healthy, and nutritious options with a focus on Jusu cold-pressed juices. Jusubar.com offers home delivery of refrigerated plant-based beverages consisting of cold-pressed juices and packaged juice cleanses. Through its Shopify enabled eCommerce sites getjusu.com and urbanjuve.com, Better Plant sells plant-based personal care products and cleaning products. Better Plant products are sold through a network of online and brick and mortar retail locations including Whole Foods Market, Pharmasave, Healthy Planet and Vitasave. Better Plant also offers operational, financial, and other services to companies with businesses that align with Better Plant’s mission to help create a better world.

For more information on Better Plant, visit betterplantsciences.com or follow on Instagram, Twitter or LinkedIn.

 

Penny White, President & CEO

penny@betterplantsciences.com

1-833-515-2677

 

Investor Relations:

Alexandra Dumanski

invest@betterplantsciences.com

1-833-515-2677

 

Sales Inquiries:

Amber Allen, Head of Sales

amber@betterplantsciences.com

604-808-8118

 

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better Plant cautions readers not to place undue reliance on forward-looking statements provided by Better Plant, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better Plant expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Posted on

Psychedelic music studio changes your attachment style: issue 22

Here’s what’s in store for you in today’s issue:

🍄 Psychedelic music studio receives $4.5M in funding

🍄 How your attachment style affects your trip

🍄 First-ever study with direct psilocin

🍄 A new helmet to understand the brain

🍄 And more.

Be sure to check out last week’s Daily Mushroom podcast:

The DMT Cure for Chronic Pain and PTSD

Kieran, a retired black ops vet who magically cured his neck pain with a wild DMT trip. Kieran talks about being in a constant stress state while serving and how psychedelics help him cope with ongoing PTSD.

Therapeutic banner

First-ever study with direct psilocin

When psilocybin is consumed, it’s metabolized into psilocin, which is the compound that produces most (or all) of the psychedelic effects.

Will the experience change if psilocin is administered directly?

Filament Health (FH) just received FDA-approval for a first-of-its kind study that will reveal the answer.

The phase I trial at the University of California San Francisco will compare the effects of psilocybin and psilocin in 20 healthy patients. Psilocybin will be administered orally, whereas psilocin will be administered both orally and sublingually, meaning it will be absorbed through tissues under the tongue.

Researchers predict that direct psilocin could result in faster onset times, greater consistency and bioavailability — with fewer side effects.

A faster treatment for depressed moms

Existing treatments for post-partum depression take up to 8 weeks and often separate the mother from her baby for long periods of time, creating even more stress.

Field Trip Health (FTRP) is developing a proprietary psychedelic to change this.

The formulation, FT-104, could be administered in just one day and lasts 2-3 hours shorter than pure psilocybin. The compound leaves the mother’s system in just 24 hours, allowing her to safely breastfeed again.

FT-104 is currently in preclinical evaluation with phase I trials expected to begin in Q1 of next year.

atai accelerates schizophrenia research after promising findings

atai Life Sciences (ATAI) developed a new compound that could help treat cognitive impairment associated with schizophrenia.

The compound, RL-007, was tested on a cohort of 8 schizophrenic patients while continuing with their antipsychotic treatments. Using brain mapping and other biomarkers, researchers found that formulation improved cognition by activating receptors linked to learning and memory. 

The findings were so promising that atai decided to spend additional resources to accelerate the compound into a Phase 2a trial, which should be completed by the end of the year.

Ending the PTSD crisis

The lack of effective PTSD treatments is “a crisis,” according to the PTSD Psychopharmacology Working Group. About one in 20 people in the UK suffer from PTSD, and current treatment options are ineffective for 40% of patients.

COMPASS Pathways (CMPS) is launching a phase II trial to see if its psilocybin therapy model for treatment-resistant depression can bring relief to patients with PTSD.

The trial will assess 20 patients who experienced trauma as adults. They will be given a single dose of the psilocybin formulation followed by 12 weeks of therapy protocols.

Researchers will measure the safety of the drug as well as improvements in PTSD symptoms, functionality, and quality of life.

inspirational banner

Psychedelic music studio receives $4.5M in funding

When patients have a positive response to music during psychedelic therapy, they’re more likely to have a mystical experience which can lead to a more effective treatment.

That’s why neuroscientist Dr. Mendel Kaelen co-founded Wavepaths – a music studio that uses AI to create customized music—on the fly—in response to a patient’s emotional state!

The implications of Wavepaths go far beyond psychedelic therapy: hospitals, birth clinics, hospice centers, and schools are showing interest in the technology. It is already being used in 30+ countries and over 5,000 practitioners await its public release.

How your attachment style affects your trip

If you’ve ever struggled with attachment anxiety in your relationships, there’s promising evidence that psilocybin could be an effective treatment:

After undergoing individual therapy, group therapy, and a single psilocybin session, a group of 18 male AIDS survivors showed significantly reduced scores for attachment anxiety – an attachment style characterized by clinginess, fear of abandonment, and difficulty trusting others.

There were no significant changes in attachment avoidance, which is characterized by repressing emotions and discomfort with close relationships.

However, high attachment anxiety scores were associated with a greater chance of mystical experiences, whereas high attachment avoidance scores were linked to grief, fear, physical distress, and paranoia during the trip.

What better way to feel more secure in your relationships than through a trip? 🤩

Old Town Road to success

Lil Nas X was honoured as a visionary at the Wall Street Journal’s Innovator Awards after releasing his latest album, ‘Montero.’ Were magic mushrooms the secret behind his success?

The artist says that his first-ever mushroom trip was a pivotal moment while recording the album. The experience helped him reflect on himself and break free from feelings of self-consciousness.

“I was able to open up a lot. I was able to write actual stories about my life and put it into my music. I actually did that for the first time,” Nas explained.

business banner

A new helmet to understand the brain

The LA-based company Kernel developed a brain-imaging helmet that can track what actually happens in the brain during a psychedelic trip.

The device, Kernel Flow, was just approved by the FDA to be used in a ketamine trial sponsored by Cybin (CYBN).

Researchers will use the helmet to measure the neurological activity of 15 patients during a ketamine therapy session compared to baseline activity.

Kernel Flow is much less expensive than other brain-imaging tools and allows the patients to move freely during the session.

Trip at home with a psychedelic patch

PharmaTher (PHRM) and Revive Therapeutics (RVV) are entering into a research agreement to develop psychedelic patches that could be used at home!

The biodegradable patches will use microneedles to deliver both micro and macrodoses of psilocybin, ketamine, MDMA, LSD, DMT, ibogaine, and mescaline.

PharmaTher is currently studying the effects of the psilocybin microdose patch, with results expected by the end of this month.

The companies aim to create a delivery method that’s safe and convenient enough for patients to administer on their own, without supervision.

PharmaTher (PHRM) and Revive Therapeutics (RVV) are entering into a research agreement to develop psychedelic patches that could be used at home!

The biodegradable patches will use microneedles to deliver both micro and macrodoses of psilocybin, ketamine, MDMA, LSD, DMT, ibogaine, and mescaline.

PharmaTher is currently studying the effects of the psilocybin microdose patch, with results expected by the end of this month.

The companies aim to create a delivery method that’s safe and convenient enough for patients to administer on their own, without supervision.

Creating a myriad of drugs with AI

Using an AI drug discovery program, Mydecine (MYCO) successfully added a novel psilocin analogue with improved delivery and stability to its pipeline.

The AI technology synthesizes billions of drug candidates and filters them based on psychedelic-related targets such as how they bind to receptors.

Mydecine also filed a patent for nanoemulsion technology. Nanoemulsion can:

  • help the company develop compounds inspired by traditional plant medicines such as reishi and cordyceps mushrooms
  • improve control in delivery, which is critical in microdosing and customizing dosages
  • advance development of over-the-counter consumer products
legal banner

Detroit decriminalizes psychedelics!

With a 61% to 39% win, Detroit became the fourth city in Michigan to widely decriminalize possession and therapeutic use of psychedelics.

Over 80% voted to establish a reparations committee that will address historical discrimination against Black communities through housing and economic development programs.

Industry Quick Hits

Oct 29 – Oppenheimer initiates COMPASS Pathways (CMPS) with a buy rating and $50 price target Read more…

Oct 29 – Braxia Scientific (BRAX) Announces Voting Results from the Annual General Meeting of Shareholders Read more…

Nov 1 – Blackhawk Growth’s (BLR) MindBio Therapeutics Looks to Expand Microdosing Clinical Trials Read more…

Nov 1 – Algernon Pharmaceuticals (AGN) reports positive pre-clinical data on DMT candidate to treat stroke Read more…

Nov 1 – Small Pharma (DMT) reports second quarter highlights Read more…

Nov 2 – Braxia Scientific (BRAX) Graduates First Cohort of Medical Professionals From Psilocybin-Assisted Therapy Training Program Read more… 

Nov 2 – U.S. FDA Approves Nova Mentis (NOVA) Orphan Drug Application Read more…

Nov 2 – Tryp Therapeutics (TRYP) Submits IND Application for Phase 2a Clinical Trial in Fibromyalgia Read more…

Nov 3 – Amanita Muscaria Mushroom Successfully Added to the Natural Health Products Ingredients Database (NHPID) of Canada Read more…

Nov 4 – Awakn Life Sciences (AWKN) Announces The Findings From Phase II A/B Study Are To Be Published In American Journal Of Psychiatry Read more…

Nov 5 – Novamind (NM) Reports FY2021 Financial Results and Operating Highlights Read more…

Nov 5 – NeonMind (NEON) Biosciences Named As A Top Industry Innovator In Inaugural Issue Of Psychedelia Magazine Read more…

Video of the Week

Trippy Mushroom-Themed Resort

Playlist of the Week

60s - 70s stoner rock
Posted on

Creso Pharma to enter Swiss medicinal cannabis market

Creso Pharma to enter Swiss medicinal cannabis market

Highlights:

  • Non-binding LOI secured with Innuana AG Switzerland, a licensed cannabis grower to enter the Swiss medicinal cannabis market
  • Innuana will grow medicinal cannabis based on Creso Pharma’s specifications – Creso Pharma to market to doctors and patients
  • LOI has the potential to significantly broaden Creso Pharma’s product offering for the Swiss market, with sales to add to the Company’s growing revenue profile
  • Execution of LOI follows recent Swiss law amendments providing a more favourable operating environment and highlight ongoing acceptance of medicinal cannabis
  • Initial sales focus with oncologists and oncological clinics in Switzerland – Creso Pharma will benefit from established relationships with the medical community over several years
  • Unlocks a large market opportunity for Creso Pharma –expected to be over 110,000 medicinal cannabis patients in 2022i in a market growing to $1.9Bn in value by 2028ii
  • Creso Pharma to leverage established networks with doctors and clinics in the Swiss market to drive growth
  • With the new laws, the commercial export of cannabis for medical purposes will also be permitted providing additional opportunities
  • Expansion of Swiss operations highlights the Company’s broader global scale up

Creso Pharma Limited (ASX: CPH, OTC: COPHF FRA:1X8) (‘Creso Pharma’ or ‘the Company’) is pleased to advise that it secured a non-binding Letter of Intent (“LOI”) with a licenced cannabis grower Innuana AG, Switzerland (“Innuana”) to grow and market medicinal cannabis for the burgeoning
market in Switzerland.

Innuana is focused on the research, growing, processing and production of medicinal grade cannabis. The group has been involved in cannabis cultivation, breeding and research for several years. Innuana has an established reputation in Switzerland and in October 2021, received one of the initial public
orders to grow cannabis by the local government to cover the needs of the City of Zürich in 2022 and beyond.

Both Creso Pharma and Innuana have executed the LOI agreement following recent amendments to the Swiss Narcotics Act in March 2021, which facilitates the patient access for the use of medicinal cannabis in Switzerland.

Following the change of the regulations, the cultivation, processing, production and trade of medicinal cannabis will become subject to the authorisation and control system of the Swiss agency for therapeutic products, Swissmedic. Accordingly, treatment with medicinal cannabis will no longer require an exceptional authorization by FOPH (Federal Office of Public Health)iii.

The legislative shifts will enable Creso Pharma to expand its Swiss operations and enter into the Swiss medicinal cannabis market. Under the LOI, Innuana will grow and produce medicinal cannabis products to the Company’s specifications, which Creso Pharma will sell and distribute to patients.

The initial term of the agreement is one year (“Initial Term”) and will automatically renew after one year (“Renewal Term”), unless either party notifies the other of their decision to not renew the agreement within 30 days prior to the expiry of the Initial or Renewal Term. Initial Term and Renewal
Terms are subject to termination for cause upon notice by either party, or upon failure to meet the above referenced renewal conditions. Should the parties not enter into a formal commercial agreement on or before 30 December 2022, the LOI shall automatically terminate.

Creso Pharma will bring in its medical and pharmaceutical expertise for the growing specifications, and the marketing and use of the product. Creso will also leverage its established relationships with prescribers and clinics in Switzerland to drive prescription sales growth.

Initially, Creso Pharma will focus on the Swiss market, which provides access to a potential 110,000 Swiss patients in 2022i in a market expected to grow to CHF1.3Bn (A$1.9Bn) by 2028ii. Additional expansion efforts into other countries will follow in due course.

Creso Pharma’s Director of International Operations, Mr Jorge Wernli said: “Recent regulatory shifts in Switzerland have unlocked a significant opportunity for Creso Pharma and this collaboration with Innuana marks the first step in our expansion into the Swiss prescription market.

“Healthcare professionals will now be able to prescribe medicinal cannabis products to a large range of patients and importantly this agreement will allow Creso to grow cannabis to its own specifications, utilising pharmaceutical experience and product expertise.

“Initially, we will focus on Switzerland with the medium-term objective to export the products into countries with similar opportunities.”

-Ends-

Authority and Contact Details
This announcement has been authorised for release by the Board of Directors of Creso Pharma Limited.

For further information, please contact:
Investor Enquiries
Creso Pharma Limited
E: info@cresopharma.com
P: +61 (0) 497 571 532
Enquiries can be texted to +61 (0) 497 571 532

Released through:
Ben Jarvis, Six Degrees Investor Relations: Ph: +61 (0) 413 150 448
ABN: 89 609 406 911
Suite 5 CPC, 145 Stirling Highway, | Nedlands, WA, 6009 | Australia
Allmendstrasse 11 | 6310 Steinhausen | Schweiz
CresoPharma.com
(ASX: CPH)

About Creso Pharma
Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the
highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.

Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which
enhance the bioavailability and absorption of cannabinoids. To learn more please visit:
www.cresopharma.com

About Innuana
Innuana is a GMP grade, licensed cannabis grower based in Switzerland with indoors and outdoors
growing operations. It employs upwards of 20 people and is a subsidiary of Uana Holding AG. In
October 2021, Uana Holding received an order from the city of Zürich to produce cannabis to cover its
needs. Innuana differentiates itself through its extensive strengths and skillset, including

  • Expertise in plant breeding, GMP and medical hemp know-how
  • Existing business as a basis
  • Own and rented fields including cultivation
  • Controlled cultivation areas with all required regulatory approvals
  • Technical expertise
  • Stable core team with unique expertise
  • Outstanding pioneering know-how in SGF 3 (medical cannabis)
  • Leading market recognition

Creso Pharma offices:
Australia
Suite 5 CPC, 145 Stirling Hwy, Nedlands, WA, 6009
Switzerland
Allmendstrasse 11, 6310 Steinhausen, Schweiz
Canada
59 Payzant Driver, Windsor, Nova Scotia, B0N 2TO
Canada
50 Ivey Ln, Windsor, Nova Scotia, B0N 2TO

Forward Looking statements
This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as “may”, “will”, “expect”, “estimate”,
“anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations. The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors,
competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent
required by applicable laws.

i Berner Zeitung: “110’000 patients will soon get cannabis legally”, 18.12.2020
ii Prohibition Partners – The European Cannabis Report: 6th Edition iii Info on the amendments to the Narcotics law in Switzerland, website of the Federal Office of Public Health
(FOPH): https://www.bag.admin.ch/bag/de/home/medizin-und-forschung/heilmittel/med-anwend-cannabis/gesetzesaenderungcannabisarzneimittel.html. The information is available in German, French and Italian: https://www.bag.admin.ch/bag/en/home/gesundleben/sucht-und-gesundheit/cannabis/pilotprojekte.html.

Posted on

A better way to get drunk: issue 21

Here’s what’s in store for you in today’s issue:

🍄 The future of psychedelics, according to an expert

🍄 A better way to get drunk

🍄 A first-of-its-kind severe anxiety study

🍄 The race for a dementia treatment

🍄 And more.

Be sure to check out this week’s Daily Mushroom podcast:

The DMT Cure to Chronic Pain and PTSD

Kieran, a retired black ops vet who magically cured his neck pain with a wild DMT trip. Kieran talks about being in a constant stress state while serving and how psychedelics help him cope with ongoing PTSD.

Therapeutic banner

A better way to get drunk

This psychedelic makes you feel drunk. Could it be used to treat alcoholism?

5-Methoxy-2-aminoindane (MEAI) is a synthetic molecule that simulates the euphoric feeling of alcohol while reducing the desire to drink.

Pre-clinical studies conducted by Clearmind Medicine Inc. (CMND) show promising evidence that MEAI could treat alcohol use disorder (AUD) and binge drinking. Clinical trials are expected to begin in the second half of 2022. 

The company just signed a development and supply agreement with Aragen Life Sciences to manufacture the molecule.

First-of-its-kind study on severe anxiety

Monash University just got the go-ahead to conduct a first-of-its-kind study!

Yesterday, the Australian university received ethics approval for a triple-blinded, active-placebo-controlled study that will investigate psilocybin-assisted psychotherapy as a treatment for severe Generalized Anxiety Disorder (GAD).

Researchers are looking to recruit 72 patients for the study, which will be conducted in partnership with Incannex Healthcare Ltd (IHL).

The therapists facilitating the study will have the option to undergo their own psilocybin session to better understand what the patients will experience.

Does neuroplasticity benefit healthy people too?

Psychedelics clearly have a huge impact on people with mental health issues, but how do they impact people who are already mentally healthy? A new research project at University College London will give us more insights!

After two years of planning, the university is launching the “Understanding Neuroplasticity Induced by Tryptamines” or UNITy Project.

UNITy Project will use fMRI scans, eye-tracking, and experience sampling to understand how the naturally functioning brain responds to various tryptamines (psychedelics that bind to serotonin receptors, such as psilocybin).

The first study will evaluate how DMT affects language processing, sensory processing, and memory in both healthy participants and heavy drinkers, and if neuroplasticity drives the results.

inspirational banner

The future of psychedelics, according to this pioneering researcher

Rick Doblin, a pioneering psychedelic researcher and activist, made some interesting predictions about the future of psychedelics in the US:

  • MDMA will be FDA-approved by the end of 2023, with psilocybin following a year or two after.
  • By 2023 or 2024, there will be 6000+ psychedelic therapy clinics (there are currently about 1000). Every town with a hospice center will have enough demand for a psychedelic clinic.
  • By 2030, one million MDMA therapy sessions will have been administered by 25,000 trained therapists.
  • A licensed legalization model could be implemented around 2035 in which patients can earn a license to use psychedelics outside the clinic once undergoing a supervised session.

Doblin is hopeful that the tremendous impacts on mental health will result in a spiritualized society that “has finally come to the point of embracing global thinking, global humanity, and dealt with economic inequity.”

Donation heals traumatized children

“We’re all traumatized children running around in adult bodies, and (psychedelic) medicines can help us all,” according to venture capitalist Sanjay Singhal.

That’s why his charity donated $5 million to launch The Nikean Psychedelic Psychotherapy Research Centre at Toronto’s University Health Network (UHN).

The centre will study psilocybin therapy as a treatment for terminally-ill patients, patients with body dysmorphia, families who have lost a child, and grieving caregivers. It will also study 5-MeO-DMT as a PTSD treatment and will train therapists to administer psychedelic therapy.

Singhal, who was diagnosed with bipolar disorder in his 30s, was inspired to fund psychedelic research after a psilocybin trip helped him break down his emotional walls and fix his relationships.

Can shrooms make you a better leader?

Magic mushrooms may have been the key to this NHL legend’s success.

Mark Messier, the only NHL player to lead two different teams to Stanley Cup championships, said that a magic mushroom trip at age 19 sparked his interest in spirituality and the power of the mind.

“I had no idea the mind was that powerful. Obviously it turned out to be an amazing experience, but more important was the question afterwards: wow, how can I use my mind to empower myself to be a better player, to be a better person, to have more energy, to create a better aura?”

The trip inspired Messier to learn about Eastern philosophies, Buddhism, Indigenous spirituality, and meditation, which had a major influence on him both as a player and a leader.

business banner

Tripping on an island to help frontline workers

Cybin (CYBN) is sending therapists on a psychedelic retreat so they can learn how to provide support to frontline healthcare workers.

Clinical trial facilitators will head to a small island in Washington to be trained on Cybin’s new EMBARK therapy model and gain experiential knowledge of psychedelics. The EMBARK model combines aspects of several psychotherapy models and incorporates patients’ spiritual experiences, bodily experiences, and relationships into the healing process.

The retreat will prepare the facilitators for an upcoming clinical trial at the University of Washington that aims to treat healthcare workers suffering from COVID-related distress, depression, anxiety, and PTSD.

Optimizing the DNA of plant medicines 

Delic Labs of Delic Corp (DELC) is partnering with GT Research Inc. to help mushroom and cannabis producers optimize their products. 

Through the deal, Delic Labs will use DNA analysis to evaluate the commercial value of different cannabis and psychedelic mushroom strains based on certain gene traits. The services will help Canadian producers optimize their compounds through genetic engineering to produce more effective plant medicines.

Which company will develop a dementia treatment first?

If treatments don’t improve, the number of Americans battling Alzheimer’s is expected to nearly triple by 2050 — reaching $1.1 trillion in care costs.

Fortunately, two more companies joined the race to develop a new treatment using psychedelics!

On Tuesday, MYND Life Sciences (MYND) acquired IP rights from Cava Healthcare Inc. for dementia treatments using psilocybin and other psychedelics. It received the assets in exchange for 450,000 shares at $0.85 each, plus $120,000 and an annual royalty fee.

Silo Pharma Inc. (SILO) also joined the race this week through a sponsored research agreement. The company will work with Columbia University to develop a psychedelic treatment that could halt or reverse Alzheimer’s.

Researching ADHD treatments in Korea

These companies are joining forces to develop unique treatments for a range of debilitating conditions.

Agtech Global International Inc. (AGGL) and  KRTL Biotech Inc. are partnering to develop CBD and psilocybin-based medicines to treat conditions like ADHD, pain from cancer, autism, PTSD, depression, and addiction.

The agreement will leverage KRTL’s team of researchers in the US and Korea, where they have already received the Korean equivalent of FDA approval to study the compounds.

Several other companies are supporting the research project including Here To Serve Holding Corp. (HTSC) and Pervasip Corp. (PVSP).

legal banner

Here’s what you missed:

  • Next Tuesday, Detroit will vote on a bill to decriminalize possession and therapeutic use of entheogens including psilocybin mushrooms, ayahuasca, and peyote. Read more…
  • A DC non-profit called The Plant Medicine Coalition issued $50K in grants to community organizations that promote psychedelic education and reform thanks to donations from Dr. Bronner’s soap company. Read more…
  • Dr. Bronner’s is also funding a lobbyist group that’s working to legalize psilocybin for therapeutic uses in Connecticut. Read more…

Industry Quick Hits

Oct 25 – HAVN Life (HAVN) Announces Departure Of Rick Brar As Director Read more…

Oct 26 – Nova Mentis (NOVA) Earns Psilocybin Orphan Drug Designation in Europe for Fragile X Syndrome Read more…

Oct 27 – Mindset Pharma (MSET) Reports Fiscal Year 2021 Financial Results and Provides Corporate Update Read more…

Oct 27 – PharmaTher (PHRM) Provides Business Update and Releases Financial Results for the First Quarter of Fiscal 2022 Read more…

Oct 28 – Blackhawk Growth’s (BLR) Subsidiary MindBio Therapeutics Appoints Patrick Moher as Advisor Read more…

Oct 28 – Greenbrook TMS (GTMS) Announces Dates For Its Third Quarter 2021 Financial Results Read more… 

Oct 28 – MYND Life Sciences (MYND) Announces Appointment of New Director Read more…

Oct 29 – Blackhawk Growth (BLR) Files Fiscal Year Ended June 30, 2021 Financial Reports Read more…

Video of the Week

Trip with your breath: Intro to holotropic breathwork

Playlist of the Week

Lo-Fi | psychedleia
jack O' lantern mushroom
Posted on

Autistic children try microdosing at a psychedelic farmer’s market: issue 20

Here’s what’s in store for you in today’s issue:

🍄Autistic children try microdosing

🍄 Group psychedelic therapy cures depression

🍄 Psychedelic farmer’s markets?

🍄 DMT granted innovative medicine designation

🍄 And more.

You’ll want to stay till the end to learn how someone found enlightenment on a trippy hike.

(Did a good friend forward this to you? If so be sure to subscribe here)

Be sure to check out this week’s Daily Mushroom podcast:
The Truth About Psilocybin and the Brain

Julia Joyes is a neuroscientist and research director at TheraPsil, a leading non profit organization making a difference to mental health in Canada. In this episode, we take a closer look at psilocybin’s impact on the brain. 

Therapeutic banner

The first study investigating psilocybin’s impact on children

According to preclinical research conducted by Nova Mentis (NOVA), psilocybin has potential to reduce anxiety in autistic patients and could improve cognitive function in patients with fragile x syndrome (FXS), a genetic condition that causes learning impairments.

Now, the company is forming a joint venture with Mycrodose Therapeutics to accelerate R&D into the treatment. The partnership will use Mycrodose Therapeutics’ patented systems to deliver a self-administered and non-invasive microdose.

The joint venture plans to conduct human clinical trials on a broad range of patients with FXS and autism, including pediatric patients. This will be the first study investigating psilocybin’s impact on children.

Group psychedelic therapy cures depression!

On Tuesday, Compass Pathways (CMPS) received a US patent for COMP360, its proprietary formulation of crystalline psilocybin. On Wednesday, the company announced positive findings from an open-label study using the formulation to treat depression in cancer patients.

Thirty patients were administered COMP360 in group therapy sessions of two to four people. Twenty-four people experienced at least a 50% reduction in depression symptoms within three weeks of treatment, which was sustained at week eight, and fifteen people were in total remission from depression.

The average depression score dropped from 25.9 to just 6.8!

The company notes that the study was not blinded or placebo-controlled, so the findings are subject to expectancy bias, but the results show promise that both COMP360 and group therapy models are effective.

Trip your way to a healthier lifestyle

Psychedelics improve mental health, but can that translate into better physical health too?

A recent study found that people who have tried psychedelics at least once in their life had a 23% lower chance of heart disease and a 12% lower chance of diabetes in the past year.

Other research indicates that psychedelic use is tied to healthier lifestyle choices such as increased exercise, reduced smoking and alcohol consumption, and a balanced diet.

Researchers also theorize that psychedelics could stimulate brain receptors that are linked to both mental and cardiometabolic health.

inspirational banner

DMT receives innovative medicine designation

DMT-assisted therapy could be approved in the UK sooner than expected!

Yesterday, Small Pharma (DMT) received an Innovation Passport Designation for its DMT-assisted therapy program for depression – a status given to promising medicines to expedite development. The passport gives the company access to the Innovative Licensing and Access Pathway (ILAP) to reduce time to market and facilitate patient access to the treatment.

The designation is essentially the UK’s version of a Breakthrough Therapy Designation, which the FDA granted to Compass Pathways (CMPS) and Usona Institute in 2018 and 2019, respectively, for their psilocybin-assisted therapy programs.

Small Pharma also launched a Phase 2a clinical trial for DMT-assisted therapy on Tuesday and began trading on the OTCQB market on Wednesday under the symbol “DMTTF”.

The largest psychedelic event in history

Curious about the latest advancements in psychedelic medicine, psychedelic retreats, microdosing, or the role of technology in the psychedelics sector? Then you won’t want to miss Microdose HQ’s Wonderland: Miami – the largest psychedelic medicine business event to date!

The two-day event on Nov. 8-9 will have keynote presentations from some of the biggest names in the psychedelic sector including including Robin Carhart-Harris, Matthew W. Johnson, Rick Doblin, and David Nutt.

(Mike Tyson and Lamar Odon will also share their experiences with psychedelic healing!)

The speakers will cover a vast range of unique topics: 

  • Shamanic protocols for making investment decisions…
  • Psychedelics and sports…
  • The threat of corporate domination in the industry…
  • And more.

Get your your ticket or virtual access pass here!

business banner

Be an early investor 🤑

Want to be an early investor in a psychedelics company? Now’s your chance!

Ei.Ventures is currently looking to raise $50M through a Regulation A+ Framework – a type of offering that allows the general public, not just institutional or accredited investors, to buy shares in a company before it goes public.

“I’m really passionate about democratizing investment opportunities so any investor can reap the rewards, and take all of the risks of early investment in game-changing companies,” said David Nikzad, the company’s founder, who was an early investor in Airbnb , Betterment, and Vidyard.

Ei.Ventures is developing a transdermal psilocybin patch and is preparing to launch a functional mushroom line early next year. Shares are selling for $4.94 each with a minimum purchase of 101 shares, and the company has already raised $20M. Take advantage of the offer here.

The world’s biggest psychedelic therapy provider

Field Trip Health (FTRP) just got one step closer to reaching its goal of running 75 psychedelic therapy clinics by 2024.

The company opened three new treatment centers in Seattle, Vancouver and Fredericton. It now administers ketamine-assisted therapy at eight clinics across North America and one in Amsterdam.

The treatment is proving to be effective with clients’ depression scores dropping from an average of 17 (severe) to 6 (mild) and benefits lasting at least 120 days.

74 studies on 50 compounds 🤯

This week, Cybin Inc. (CYBN) completed its 74th preclinical study to advance its proprietary molecules, CYB003 and CYB004, toward clinical research.

The company has evaluated 50 novel compounds in its preclinical research, narrowing it down to four lead candidates. including CYB003 for alcohol use disorder and CYB004 for anxiety disorders.

Compared to classic psychedelics, the formulations are showing:

  • Faster onset times
  • Shorter durations
  • High oral bioavailability
  • Significant brain penetration, and
  • Less variability between subjects

Human clinical trials are expected to begin early next year to work toward an Investigational New Drug (IND) status.

legal banner

Psychedelic farmer’s markets coming to Cali!

Oakland could legalize the sale of psychedelics as early as next year!

The city decriminalized the use and cultivation of many psychedelics back in 2019, and now, activists are building on their progress with a “Go Local” Legislative Initiative. The initiative would create a community-based model to allow people to legally purchase natural psychedelics like psilocybin and ayahuasca from local producers.

The initiative will gather research on how best to implement the model over the next year and will introduce a legislation in the summer of 2022.

Some possible reforms being considered include allowing commercial agriculture in residential zones, creating “sacred plant adult farmer’s market permits,” and allowing cannabis dispensaries with 100% local ownership to sell entheogens, among many others.

All products would have to be grown, produced, and tested locally.

Another unanimous win 🎉

After yet another unanimous vote, Easthampton became the fourth city in Massachusetts to decriminalize possession and cultivation of psychedelics!

Will this European island legalize shrooms?

Malta may legalize cannabis, but residents don’t want the reforms to stop there.

In a recent survey, 447 people in Malta were asked if they think the country should legalize any other substances beyond cannabis. Magic mushrooms was the most popular response with 45% in favour of its legalization.

LSD was the next most common response at 27%, but 56% did not see a need for any other drugs to be legalized.

Industry Quick Hits

Oct 18 – Johns Hopkins Receives $4M from the NIH – The First Federal Grant for Psychedelic Research in 50 years Read more…

Oct 19 – FSD Pharma (HUGE) Signs Agreement With Covar Pharmaceuticals To Support The Development Of Lucid-Psych Read more…

Oct 19 – Psyched Wellness (PSYC) says preliminary data reveals potential new functional property of Amanita mushroom for treating skin conditions Read more…

Oct 19 – Bank Of America Shuts Down Account Of Cannabis & Psychedelics Research Institute Registered With DEA Read more…

Oct 19 – atai Life Sciences (ATAI) Launches atai Impact, a Philanthropic Program to Harness the Power of Innovative Mental Health Approaches for Positive Social Change Read more…

Oct 20 – Tryp Therapeutics (TRYP) Reports Clinical Hold on Proposed Phase 2a Study in Eating Disorders Read more… 

Oct 20 – LOVE Pharma (LUV) Announces Development of Muco-Adhesive Sublingual Psilocybin Strip Read more…

Oct 21 – Journal of the Royal Society of Medicine Publishes New COVID-19 Suicide Research Led by Braxia Scientific (BRAX) CEO Dr. Roger McIntyre Read more…

Oct 22 – Novamind (NM) Unveils Stealth Mode Investment in Alto Neuroscience Read more…

Video of the Week

Dr. Bronner’s Support for Psychedelic-Assisted Therapy and Plant Medicines

Playlist of the Week

Lo-Fi | psychedleia
mushrooms on scale
Posted on

Elon takes shrooms to the moon!: issue 17

Here’s what’s in store for you in today’s issue:

🍄 Struggling with negative self image

🍄 Pneumonia drug + shrooms repair the brain?

🍄 Build your brain without getting high

🍄 Is Elon going to take shrooms to the moon?

🍄 And more.

You’ll want to stay till the end to learn how someone became a cartoon on magic truffles!

(Did a good friend forward this to you? If so be sure to subscribe here)

Be sure to check out last week’s Daily Mushroom podcast!
Psilocybin, is it the next cannabis wave?

In this episode we have Lenny Kerman, a strategic financial consultant who works with various psilocybin and cannabis companies. He talks about how he’s invested in the space and has some valuable information for those looking to invest as well.

Therapeutic banner

Struggling with a negative self image?

A recent study suggests that repeated psychedelic drug use may be effective in reducing PTSD symptoms and internalized shame in people who endured maltreatment during childhood.

The researchers surveyed adults with severe physical, emotional, or sexual trauma and found that those who took psychedelics for therapeutic purposes (in non-clinical settings) were less likely to have a negative self-concept or disturbances in relationships.

Participants who used psychedelics with therapeutic intent 5 times showed the lowest levels of internalized shame and complex trauma.

Enhancing psilocybin…with a pneumonia drug?

A drug that loosens mucus in the lungs could also help treat concussions!?

Lobe Sciences (LOBE) discovered that psilocybin might work better when paired with N-Acetylcysteine (NAC), a drug used to treat Tylenol overdose and respiratory conditions like pneumonia, bronchitis, and asthma.

In rodent models of mild traumatic brain injury (TBI) and PTSD, the combination of psilocybin and NAC performed significantly better than psilocybin, NAC, or a placebo alone.

The company is working on finding a supplier of high purity cGMP psilocybin to continue research and expand on these findings.

Reducing fish seizures

This Vancouver company is making advancements across its drug pipeline.

Dravet Syndrome, a disorder that causes epilepsy from a young age, is the target of a new study by Bright Minds (DRUG). In preclinical studies on zebrafish, DRUG was effective in reducing seizure duration and frequency and is now on track to be tested in human trials early next year.

In rat models, DRUG showed efficacy in treating opioid use disorder and binge eating disorder with rats demonstrating a 50% reduction in binge eating episodes.

The company also has a mixed compound that is in preclinical development for cluster headaches, chemotherapy-induced peripheral neuropathy, and other pain disorders.

inspirational banner

Tripping in Times Square

This week, the first-ever psychedelic billboard campaign debuted in Times Square to spark a conversation about the healing power of plant medicines and disrupt profit-driven ads.

The #CelebratePlantMedicine campaign encourages viewers to share their personal experiences with plant medicines to destigmatize the use of psychedelics. It also aims to amplify the importance of set and setting, integration, and respecting Indigenous wisdom.

The campaign is run by DoubleBling Magazine, Musings Magazine, Rainbo Mushrooms, and Honeysuckle Magazine, which ran Time Square’s first cannabis billboard.

Go share your story with the hashtag to join the movement!

3 women + microdosing = )

Chelsea says that microdosing allows her to “stay fully present” and is the only tool that helps her focus her busy mind, but the biggest shift was in her anxiety. “For over fifteen years, I had severe anxiety, but through microdosing, I could sit with and deliberate my fears. I now rarely suffer with it, and if I do, it’s fleeting,” she shares.

One woman, Amber, was so depressed that everything felt dull and uninteresting, until she started microdosing. “When I microdosed for the first time I found myself noticing the beauty of the things around me again,” she says. She explains that microdosing is “akin to a child-like wonder” and makes her feel “more positive, open-minded and creative but still completely functional and sober”.

Bea finds that microdosing three times per week acts as a natural mood booster and study aid, brings her mental clarity, and helps her organize her life. She says she’s now able to be her true, stable self and is no longer the “people-pleasing, anxious version” of herself.

Is Elon going to take shrooms to the moon? 

Elon Musk has been known to have a major influence on the stock market, with his Tweets causing Bitcoin and Dogecoin to skyrocket almost instantaneously. His latest interview could take shroom stocks to the moon 😉

In an interview with Ronan Levy, co-founder of Field Trip Health (FTRP), Musk was asked what role he thinks psychedelics have in “addressing some of the more destructive tendencies of humanity.”

Elon replied, “I think, generally, people should be open to psychedelics. A lot of people making laws are kind of from a different era, so I think, as the new generation gets into political power, I think we will see greater receptivity to the benefits of psychedelics.”

business banner

Build a better brain without getting high

“We are not a one- or two-asset company. We’ve got a large pipeline coming out,” warns David E. Olson, founder of Delix Therapeutics.

The Boston-based startup just raised $70 million in series A financing to develop psychedelic-inspired compounds that are safe enough to take at home.

The company has already synthesized about 1,000 compounds across 8+ classes of psychedelics, with the goal of creating compounds that form synapses between brain cells without inducing hallucinations.

The researchers have found a couple of promising contenders, which are on track to be studied in Phase 1 clinical trials by the end of this year.

Are stoners getting bored with cannabis?

These two companies are joining forces to become a leader in commercialized psilocybin extracts.

Pure Extracts (PULL), a cannabis, hemp, and mushroom extraction company, signed a Joint Venture agreement with Psyence Group (PSYG) to form “Pure Psyence”.

The agreement leverages Psyence Group’s licensed cultivation facility and standardized psilocybin mushroom supply to create high-purity, naturally-derived mushroom extracts. Yesterday, Psyence Group completed its first official validated harvest, bringing it one step closer to receiving a British Standards Institute (BSI) certification.

The combined expertise will make standardized psilocybin more accessible to Canadian research institutions and will allow Pure Psyence to conduct human clinical trials using the extracts.

legal banner

Healing the Armed Forces

The US government is funding psychedelic research to get military members the relief they deserve!

A new measure, filed by Rep. Dan Crenshaw of Texas, would allow the Secretary of Defense to award research grants to study psychedelic therapy as a PTSD treatment for active military members.

The measure would allow any State or Federal agency, academic institution, or nonprofit to study the therapeutic effects of psilocybin, ibogaine, MDMA, or 5-MeO-DMT. If passed, funds could be used for Phase 2 clinical studies involving members of the Armed Forces or to train practitioners to offer the treatment.

Another city decriminalizes psychedelics

Well, kind of…

In a 5-2 vote, Grand Rapids, Michigan approved a psychedelics decriminalization resolution, yet activists feel the measure falls short.

The resolution calls for law enforcement deprioritization for use and possession of psilocybin, peyote, ayahuasca, and ibogaine, but it doesn’t address the cultivation, purchase, transportation or distribution of the entheogens, unlike the measure passed in Ann Arbor.

On the bright side, the measure notes that the Mayor and City Commission will support efforts to decriminalize the entheogenic plants and fungi on a local, state, and federal level.

Psychedelic research coming to Florida

“The science regarding psilocybin is real, cannot be ignored, and soon will be a universally-accepted form of treatment in the U.S.,” said Rep. Michael Grieco (D) of Florida.

That’s why he and Senate Minority Leader Lauren Book (D) filed bills that would require the state to study the medical potential of psilocybin and MDMA.

The bills were modeled on the measure enacted in Texas earlier this year to study psychedelic therapy for veterans with PTSD, but with an even broader scope. If enacted, the Department of Health would be directed to research other conditions like depression, anxiety, bipolar disorder, chronic pain and migraines.

Industry Quick Hits

Sept 27 – Clearmind Medicine (CMND) To Fund Second R&D Partnership With Hebrew University’s Technology Transfer Company Read more…

Sept 27 – Nikean Foundation announces $5 million gift to create a Psychedelic Psychotherapy Research Centre at Toronto’s University Health Network (UHN) Read more…

Sept 27 – Delic (DELC) Closes C$7.0 Million Private Placement With U.S. Institutional Investor to Fuel Growth of Largest National Presence Read more…

Sept 28 – NeonMind (NEON) Advances Strategy For Specialty Clinic Launch Read more…

Sept 28 – PharmaTher (PHRM) Announces Closing of CAD$10 Million Private Placement with Institutional Investors Read more…

Sept 29 – MYND Life Sciences Inc. (MYND) Announces RSU Grant Read more…

Sept 29 – Blackhawk Growth’s (BLR) Mindbio Therapeutics Signs Collaboration Agreement With Digital Mind Technology Technology Read more… 

Sept 30 – MINDCURE Announces Commencement of Trading on the OTCQX Best Market Under Symbol ‘MCURF’ Read more…

Sept 30 – Novamind (NM) Opens 6th Integrative Psychiatry Clinic, Adds 3rd Clinical Research Site Read more… 

Video of the Week

LIFE BEYOND: Chapter 1

Becoming an extremely pleasing ball of flesh

This Reddit user had a memorable first trip on magic truffles.

“We cycled to an extremely secluded hill with trees covering it from all sides and where no one ever goes. It’s our secret chill spot mostly used for smoking weed. We sat down in pure awe of the spot and nature. Generating sentences and word combinations was EXTREMELY HARD, because every time we wanted to get a thought out, when we started explaining it, our brains had already moved on to the next thought. It was a rapid fire of thoughts and ideas and we laid down looking at the sky and the trees in silence just thinking about the universe and different topics.

Everything had patterns and colors were extremely bright and vibrant. Everything was breathing and flowing and when I looked at my phone, I couldn’t decipher words as all the letters on my keyboard and screen kept moving and switching places. I didn’t see words, but rather letter combinations. Looking at the camera, my face was constantly moving, shrinking and getting bigger. My eyes looked big and cartoony. It looked like I was living in a cartoon as everything looked like a drawing and too symmetrical to be real. At one point I pressed my head against my knee and felt like my body was merging into a ball of flesh, but it felt extremely pleasing. Everything was positive, loving and peaceful. I was at peace with myself and the universe. Orange juice tasted amazing. Me and my friend didn’t have much interaction as we were both fully engulfed in the trip. He told me afterwards that he had many similar effects to me.

At the end of the peak, I noticed my friend shedding tears and put my hand on his shoulder and asked him if everything was ok. He said he wasn’t sad, but they were rather tears of joy and acceptance. Seems like he was having an even more intense experience than me, but he said his trip was extremely good just like mine and no signs of a bad trip or negative thoughts.”

Playlist of the Week

Psychedlic and Chill
mushroom balloon
Posted on

Havn Life Announces Supply And Distribution Mou With Mycrodose Therapeutics

Havn Life Announces Supply And Distribution Mou With Mycrodose Therapeutics

The partnership is a integral step in the The Company’s path to market in the U.S., achieving one of its most important milestones to-date

Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”)a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health and enhance the capabilities of the mind, is thrilled to announce a partnership with California-based Mycrodose Therapeutics, one of only a few private companies that has been granted a Schedule I License to research four (4) psychedelic compounds including psilocybin, MDMA, DMT, & LSD by the United States Drug Enforcement Agency (DEA).

HAVN Life will work with its partners to export their naturally derived psilocybin to Mycrodose Therapeutics, where it will be used in the development of advanced drug delivery (ADD) systems to treat mental health and cognitive degenerative diseases, as well as be distributed to appropriately licenced customers in the U.S.

“We are excited to have forged this partnership with Mycrodose Therapeutics, building an important link in our supply chain to service our Supply Agreement partners in the US,” says HAVN Life CEO Tim Moore. “Mycrodose Therapeutics has a strong working relationship with the DEA, and is well-suited to manage the highly-regulated distribution requirements for psilocybin in the US. We look forward to building considerable success with them,” he adds.

Mycrodose Therapeutics is an ideal partner for HAVN Life, with a successful track-record of working with the FDA and navigating the clinic trial process, along with a proven track record of core business fundamentals and successful M&A ventures. This partnership in is a very important milestone for The Company, and will be a gateway to any appropriately licensed customer in the U.S., be they research-focused or otherwise.

​​This partnership allows naturally derived GMP psilocybin to be available here in the US for a better price than what is available to companies right now. The partnership also eases the supply chain issues currently facing the hundreds of pharmaceutical companies, research institutions, and nonprofits across the United States that can’t find psilocybin at an affordable price.

“Mycrodose Therapeutics is excited to form this mutually expansive and highly profitable partnership with HAVN Life as their exclusive distributor in the United States of naturally derived GMP psilocybin, GMP psilocybin botanical extract, and GMP psilocybin raw mushroom powder,” says Chad Conner, Chief Executive Officer at Mycrodose Therapeutics. “Today the majority of psilocybin that we find comes from synthetic sources and is lab-grown on E.coli, and we believe that the entourage-effect from psilocybin derived from the whole mushroom will be a very valuable addition to the current supply chain. This partnership helps support our company’s ambitious product development and R&D milestones by offering an alternative to synthetic derived psilocybin at a fraction of the costs, and most importantly this partnership removes all current and future supply chain issues with obtaining GMP psilocybin for our own research and the research of any US-based Institution researching psychedelics.”

With Mycrodose Therapeutics onboard, HAVN Life further consolidates its position as an early mover with its ability to supply companies with high-quality, naturally derived psilocybin as markets open up around the globe, demonstrating itself to be a supply chain leader in the industry.

On Behalf of The Board of Directors

Tim Moore

Chief Executive Officer

About Mycrodose Therapeutics

Mycrodose Therapeutics is a US-Based pharmaceutical company headquartered in San Diego, California specializing in the development of advanced drug delivery systems utilizing psychedelic compounds to treat mental health and cognitive degenerative diseases. Mycrodose is one of only a few private companies that has been granted a Schedule I License and been approved by the United States Drug Enforcement Agency (DEA), State of California Attorney General’s Research Advisory Board, and The US Food & Drug Administration (FDA) to research four (4) psychedelic compounds: psilocybin, LSD, MDMA, and DMT. The company believes that its IP-Protected Sustained Microdosing Technology™ is a smarter and safer approach to delivering pharmaceutical compounds to patients of all ages and allows for an expandable and scalable business model.

About HAVN Life Sciences Inc.

HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and innovative therapies to support brain health and enhance the capabilities of the mind.

Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally derived psychedelic compounds for research that will define the future of modern medicine. With its new line of natural health products, HAVN Life offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.

Purchase our products and find out more at yourhavnlife.com, and follow us on Facebook, Twitter,  Instagram and Youtube.

Posted on

Educated young adults are taking more psychedelics and drinking less: issue 15

Here’s what’s in store for you in today’s issue:

🍄 A different approach to treating depression

🍄 6 stocks to make you $

🍄 Healing racial trauma

🍄 A new psychedelics ETF

🍄 And more.

You’ll want to stay till the end to learn how someone travelled to different dimensions with Post Malone!

(Did a good friend forward this to you? If so be sure to subscribe here)

Be sure to check out this week’s Daily Mushroom podcast!
How Psilocybin Is Revolutionizing The Way We Die

In this episode Natasha Fearnley, the first nurse to legally experience psilocybin therapy, shares her fascinating views on palliative care.

Therapeutic banner

Can this combination treat depression?

Allied Corp. (ALID) has a new approach for treating depression, anxiety and PTSD.

The Kelowna-based company developed a proprietary formulation called Psilonex RX that combines psilocybin extract with functional mushroom extracts and a blend of vitamins.

Allied Corp. aims to treat patients by prescribing a dose of Psilonex RX followed by a daily dose of its CBD product, Psilonex Daily.

The company just began manufacturing Psilonex RX under an agreement with HAVN Life Sciences (HAVN).

Healing racial trauma

A mission to end racism, bring equity to healthcare, and treat racial trauma. Psychologist, Monnica Williams of the University of Ottawa, believes that psilocybin and MDMA can help people of colour address the trauma they’ve endured from racial biases.

“Using psychedelics can not only bring these pain points to the surface for healing, but can reduce the anxiety or response to these memories and allow them to speak openly about them without the pain they bring,” Williams says.

She notes that POC are vastly underrepresented in the mental health care sector, specifically in psychedelic-assisted therapy, and expresses the need for specialized training to work with marginalized groups.

Williams has struggled to find funding for her research in this area in the past, but she’s hopeful that her work will gain more traction with the recent increased attention to racial justice.

Tapping into traditional healing

Resurgent Biosciences, a subsidiary of Goodness Growth Holdings (GDNS), is tapping into the spiritual and cultural side of psychedelics to develop a better approach to psychedelic therapy.

The company is launching a study on the naturalistic use of entheogens through a partnership with Flor da Jurema, a temple community in Brazil where visitors can take part in spiritual experiences with traditional plant medicines.

The study, which was just approved by an independent Institutional Review Board, will survey 100 adults who have participated in entheogen therapy centers or psychedelic retreats in the last five years.

The goal is to get a sense of their intentions, motivations, experiences, demographics, and willingness to participate in entheogen research in the future and use the findings to create more positive, long-lasting results from psychedelic-assisted therapies.

inspirational banner

Educated young adults are taking more drugs and drinking less

To escape the boredom and stress of the pandemic, college students are turning to psychedelics and marijuana.

A recent study found that psychedelic drug use among college students nearly doubled during the pandemic, increasing from 5% in 2019 to 9% in 2020. For non-college young adults, use increased from 8% to 10%.

College students also reported record-high marijuana use and record-low levels of alcohol consumption and binge drinking, likely as a result of fewer social events.

Experts predict that these trends reflect need to cope with mental health issues the desire to break monotony with a different mental state.

Psychedelic journalists!

“As the field of psychedelics explodes, we’re going to need sophisticated journalism to provide the public with reliable information and the field with accountability.”

That’s where Tim Ferriss steps in.

His non-profit organization, the Saisei Foundation, just donated $800,000 over three years to UC Berkeley’s Center for the Science of Psychedelics (BCSP) to establish the Ferriss – UC Berkeley Psychedelic Journalism Fellowship.

The fellowship, which will be overseen by BCSP co-founder Michael Pollan, will support young journalists reporting on the psychedelics industry for mainstream news outlets. Journalists can apply to receive grants of up to $15,000 to investigate the science, policy, business and culture of psychedelics.

business banner

These 6 stocks will make you money 🤑

On Tuesday, the Canadian investment bank Eight Capital gave a Buy rating to 6 psychedelic stocks. Here are the projected returns:

Invest in this ETF… because YOLO 😉

New ETF alert!

Yesterday, AdvisorShares launched the first psychedelic ETF on a US exchange – NYSE: PSIL.

The portfolio manager, Dan Ahrens, has an extensive track record of managing ETFs in a variety of sectors including two cannabis ETFs, MSOS and YOLO.

The distribution of holdings is shown below:

legal banner

Michigan paves the way

Michigan could be the next state to decriminalize psilocybin!

Senator Jeff Irwin (D-Ann Arbor) introduced a bill, SB 631, that would decriminalize the use, possession, cultivation, and delivery of psilocybin and mescaline.

The bill would also allow practitioners to use the psychedelics in counseling or spiritual guidance, but commercial sales would remain illegal.

The city of Ann Arbor, Michigan has already decriminalized psychedelics, and Detroit isn’t far behind with a decriminalization initiative to appear on the ballot this November.

Go sign this petition!

A California activist group, Decriminalize California, is working to get a psilocybin legalization measure on the 2022 ballot, and they’re making progress!

The measure, called the California Psilocybin Initiative, would allow the possession, use, cultivation, social sharing, and even the retail sale of psilocybin.

This week, the group was  cleared to begin collecting signatures for the initiative- they’ll need 623,212 registered voters to sign the petition within 180 days. Luckily, 2,800 people have already volunteered to help with the process.

“I feel pretty damn good honestly [about the prospects of the initiative]. People are so psyched for psychedelics,” said the director of the campaign.

Industry Quick Hits

Sept 14 – Nova Mentis (NOVA) Applies to US FDA for Psilocybin Orphan Drug Designation Fragile X Syndrome Treatment Read more…

Sept 14 – First subject dosed in Beckley Psytech’s psilocybin trial for rare headache disorder Read more…

Sept 14 – Mindset Pharma (MSET) Further Validates Lead Candidate, MSP-1014, as a Next Generation Psilocybin Analog through Drug Discrimination Assay Read more…

Sept 17 – Enveric Biosciences (ENVB) Announces Closing of MagicMed Industries Acquisition Read more…

Video of the Week

Expert Answers Psychedelics Questions From Twitter (ft. Michael Pollan)

Seeing aliens with Post Malone

This Reddit user tapped into different dimensions after taking 2.7 grams of Penis Envy mushrooms.

“I turned on a podcast that I highly recommend to all experienced trippers after my experience with it. It was Joe Rogan and Post Malone tripping together. Once I turned on the podcast I was immediately intrigued about how I could feel their emotions and vibes and feel like I was tripping with them. All of the sudden my no-visual trip got slapped in the face when the whole tv starting started to swirl around and their eyes got all geeked out. I was about to turn it off because I didn’t want to have a artificial video of edited psilocybin visuals. I paused the video, and I realized that the screen was still moving like it was before and the visuals were REAL. At that moment in time I got excited because I knew what was about to come was gonna be good.

I turn the podcast back on and I start to zone out at the tv when I feel a rush of euphoria flowing though my body at the beat of my heart. I was manually breathing and I felt like I was gonna fall FORWARD while laying down because the end of my bed was a for some reason interrupted as a cliff my my brain. The whole room was a weird color like a color invert Instagram filter, I don’t know how to explain this in words guys, but I actually felt like I was being lifted and about to be thrown off my bed. I was gripping for dear life my god it was intense.

Then they started taking about aliens.. they said something about them being around all the time but we just can’t see them until we’re on mushrooms. BOOM fucking blast off I was seeing my own version of alien entity’s all around me. Every square inch of my peripheral vision was different species staring at me. It was incredible.

But I’d like to mention, only watch this podcast if you’re experienced because they do talk about ghosts and the most terrifying things they can think of at one point and they actually scared themselves a little bit lol. Creeped me out too because it wasn’t just stories, I FELT the ghosts and spirits. With full force I was like a skipping record player switching through dimensions on every topic they’d talk about and I felt like Post Malone was family for about three hours. I have never been so deep in my life and this is the most excited I’ve ever been about mushrooms and their capabilities of tapping into other worlds and dimensions and having realizations that you can’t EVER have sober.”

Playlist of the Week

Trippy Trance 👽
fishing for a mushroom
Posted on

Tapping into traditional healing

Goodness Growth Holdings™ Subsidiary Resurgent Biosciences Launches First IRB-Approved Research Study on Entheogens & Psychedelic Experiences

Resurgent Biosciences, a subsidiary of Goodness Growth Holdings (GDNS), is tapping into the spiritual and cultural side of psychedelics to develop a better approach to psychedelic therapy.

The company is launching a study on the naturalistic use of entheogens through a partnership with Flor da Jurema, a temple community in Brazil where visitors can take part in spiritual experiences with traditional plant medicines.

The study, which was just approved by an independent Institutional Review Board, will survey 100 adults who have participated in entheogen therapy centers or psychedelic retreats in the last five years.

The goal is to get a sense of their intentions, motivations, experiences, demographics, and willingness to participate in entheogen research in the future and use the findings to create more positive, long-lasting results from psychedelic-assisted therapies.

PDF of article

Posted on

NeonMind Announces Divestiture Of Consumer Related And Other Non-Core Assets

NeonMind Announces Divestiture Of Consumer Related And Other Non-Core Assets

Reflects Strategic Focus on Psychedelic Treatments with Major Milestones in 2021

Vancouver, B.C. – September 13, 2021: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF) (“NeonMind”, the “Company”), announced it has completed the sale of assets related to its consumer division, including e-commerce operations and underlying functional food assets, as well as shares owned in Translational Life Sciences Inc. (“TLS”), for a combined consideration of approximately C$1.1 million plus a royalty.

This follows the Company’s completion of its Integrative drug development plan by its research and development working group, which validated the Company’s path forward with its focus on psychedelic drug development programs. This includes the advancement of NEO-001, synthetic psilocybin, to treat obesity into a regulator-approved psychedelic drug product.

“Obesity  continues to be a key market for drug development due to a massive, underserved population of patients and burdensome comorbidities including depression, cardiovascular disease, and diabetes,” said Rob Tessarolo, President & CEO of NeonMind. “We have encouraging proprietary pre-clinical data showing the positive effects of psilocybin in reducing weight gain, and the published clinical data to date on the compound is promising in its ability to provide a durable response in multiple psychiatry indications. As we progress towards clinical studies in obese patients, our increased engagement with scientific and medical experts has resulted in positive feedback in the novelty of the NEO-001 program and reinforcing its potential and positioning as a valuable treatment tool”.

With the decision to focus on NEO-001, NeonMind has decided to divest its non-core assets in functional foods and early-stage discovery. NeonMind is now well positioned to more efficiently utilize capital to progress as a leading company in the transformative field of interventional psychiatry, with two divisions: 1) a pharmaceutical division focused on psychedelic drug development and 2) a medical services division focused on providing evidence-backed treatments including psychedelics.

With the pharmaceutical division, NeonMind aims to advance NEO-001 through major drug development milestones including a pre-IND meeting with the FDA and a pre-CTA meeting with Health Canada in Q4 2021 for the planned Phase 1/2 study aimed to address deficiencies in chronic weight management. With the medical services division, the company is focused on setting up a specialty clinic network providing interventional psychiatry treatments, including psychedelics, with a target to announce the first location in Q4 2021.

“Although NeonMind mushroom coffees have been well received by consumers, significant further investment is required to drive a successful consumer products business. We prefer to focus on our core competencies, which are drug development and deployment of medical services,” said Rob Tessarolo. “We are excited by the significant opportunity before us: to bring psychedelic-based treatments to market that have the potential to provide breakthrough therapies for mental illness and obesity.”

On September 10, 2021, NeonMind entered into an agreement with Better Plant Sciences Inc. (“Better Plant”), whereby Better Plant agreed to purchase the functional food assets related to NeonMind’s consumer division for C$645,000 plus a royalty of 3% of net product sales above C$1,000,000 for 25 years.  On September 10, 2021, the disposition was completed and the following assets were transferred by NeonMind to Better Plant: four  mushroom coffee products currently being sold in Canada, and four mushroom coffee dietary supplement products, including existing inventory, raw materials and packaging for all eight products, social media accounts related to the products, a domain neonmind.com and the neonmind.com Shopify-enabled website in Canada and the US, as well as associated marketing materials and a license to use the brand NeonMind in association with the products.  In consideration for the assets Better Plant paid C$645,000 including taxes, plus an agreement to pay a royalty of 3% of net product sales payable on sales over C$1,000,000 for 25 years.  The payment of C$645,000 was made by setting off the balance due on a note for C$645,000 owed by NeonMind to Better Plant which had a maturity date in February 2022.

On  August 30, 2021, NeonMind sold all of the common shares it owned in TLS for $450,000 cash to a group of purchasers. The principal purchaser was Dr. William Panenka, who is a shareholder in NeonMind and the principal of TLS.

The net result on NeonMind’s current assets of both transactions is an increase in working capital of approximately C$1.1 million.

Although each of the TLS and Better Plant transactions may be considered related party transactions pursuant to Multilateral Instrument 61-101, each transaction is exempt from the shareholder approval and valuation requirements of the instrument.

 

About NeonMind Biosciences Inc.

NeonMind operates two divisions: (i) a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; and (ii) a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings.

In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind’s lead candidate, NEO-001, employs psilocybin as an agonist at the serotonin 5- HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The Company’s second drug candidate, NEO-002, employs low-dose psilocybin as an agonist at the 5-HT2C receptor, which controls appetite.

NeonMind established a medical services division with the goal of launching NeonMind-branded specialty mental health clinics in Canada that incorporate evidence-backed innovative treatments to address a variety of mental health needs.

 

For more information on NeonMind, go to www.NeonMindBiosciences.com

 

For further information, please contact:

Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.

rob@neonmind.com

Tel: 416-750-3101

 

Investor Relations:

KCSA Strategic Communications

Scott Eckstein / Tim Regan

neonmind@kcsa.com

Tel: 212-896-1210

 

Media Inquiries:

KCSA Strategic Communications

Annie Graf

neonmind@kcsa.com

Tel: 786-390-2644

 

The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or NeonMind’s future performance. The use of any of the words “could”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on NeonMind’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, NeonMind’s drug development plans, its ability to retain key personnel, and its expectation as to the development of its intellectual property and other steps in its preclinical and clinical drug development constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. NeonMind disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.